AR031572A1 - Derivados de ribavirina, composiciones farmaceuticas y el uso de los mismos solo o en combinacion para la preparacion de medicamentos para erradicar hcv-arn en pacientes que tienen infeccion cronica de hepatitis c - Google Patents
Derivados de ribavirina, composiciones farmaceuticas y el uso de los mismos solo o en combinacion para la preparacion de medicamentos para erradicar hcv-arn en pacientes que tienen infeccion cronica de hepatitis cInfo
- Publication number
- AR031572A1 AR031572A1 ARP010101840A ARP010101840A AR031572A1 AR 031572 A1 AR031572 A1 AR 031572A1 AR P010101840 A ARP010101840 A AR P010101840A AR P010101840 A ARP010101840 A AR P010101840A AR 031572 A1 AR031572 A1 AR 031572A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nr21r22
- aryl
- alkanoyl
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen derivados de ribavirina, que comprenden un compuesto representado por la formula (1), en la cual: por lo menos uno de R2', R3' o R5' es H, R20-(W)x-CO-, R20-(W)x-CS- o R20-(W)x-PO(OH)-; y donde por lo menos uno de R2', R3' o R5' no es H; donde R20 es alquilo, H, alcanoilo, cicloalquilo, arilo, heterocíclico, NR21R22, alquenilo, o alquinilo; o es alquilo, alcanoilo, alquenilo o alquinilo substituido con halo, fenilo, cicloalquilo, NR21R22, hidroxi, alcoxi; o es arilo substituido con fenilo, halo, CN, NO2, OH, R28, OR28, CF3, SH, SR21, SOR21, SO2R21, NR21R22, CO2H, CO2-, OR21, O-M+ o S-M+; donde M+ es un cation de metal alcalino; o R20 es -(CHR21)e-(CH2)f-CO-R22, -(CHR21)e-(CH2)t-OR22, o -(CHR21)e-(CH2)f-NR21R22; W es O, NR28 o S; R21 es H, alquilo, alcanoilo, Y o arilo o es alquilo, alcanoilo o arilo substituido con halo, fenilo, CN, NO2, OH, CO2H o alcoxi; y R22 es H, alquilo o arilo, o es alquilo o arilo substituido con fenilo; halo, CN, NO2, OH, CO2H o alcoxi; o R21 y R22 tomados conjuntamente con N y uno de CHR21, NR21, O, S, SO o SO2 forman un anillo de cinco, seis o siete miembros; R27 es H, OR21, NR21R22, R20-(W)x-CO-, R20-(W)x-CS-, (HO)2PO- o R20-(W)x-PO(OH)- o HO-SO2; R28 es H, alcanoilo, arilo, alquilo o alquilo substituido con OH, halo o NR21R22; e = 0 a 6; f = 0 a 10; t = 0 a 100; s = 0 a 6000; r = 1 a 5000; y x = 0 o 1; o una sal farmacéuticamente aceptable del mismo, las composiciones farmacéuticas que los contienen así como también el uso de los derivados de ribavirina representados por la formula (1) para la preparacion de un medicamento para el tratamiento de infecciones virales susceptibles, por ejemplo, infecciones de hepatitis C cronicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19880100P | 2000-04-20 | 2000-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031572A1 true AR031572A1 (es) | 2003-09-24 |
Family
ID=22734903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101840A AR031572A1 (es) | 2000-04-20 | 2001-04-19 | Derivados de ribavirina, composiciones farmaceuticas y el uso de los mismos solo o en combinacion para la preparacion de medicamentos para erradicar hcv-arn en pacientes que tienen infeccion cronica de hepatitis c |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US6924270B2 (es) |
| EP (1) | EP1282632A1 (es) |
| AR (1) | AR031572A1 (es) |
| AU (1) | AU2001255495A1 (es) |
| WO (1) | WO2001081359A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924270B2 (en) | 2000-04-20 | 2005-08-02 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| KR20030036189A (ko) | 2000-05-26 | 2003-05-09 | 이데닉스(케이만)리미티드 | 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물 |
| US20060024270A1 (en) * | 2000-08-23 | 2006-02-02 | The New York Hospital Medical Center Of Queens | Compositions and methods for preventing or treating encephalitis with interferon |
| WO2002032414A2 (en) * | 2000-10-18 | 2002-04-25 | Schering Corporation | Ribavirin-pegylated interferon alfa hcv combination therapy |
| AU2003248748A1 (en) * | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| DE14169110T1 (de) | 2002-06-28 | 2022-05-12 | Centre National De La Recherche Scientifique -Cnrs- | Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| CN101172993A (zh) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷 |
| US8476254B2 (en) | 2002-07-02 | 2013-07-02 | Corcept Therapeutics, Inc. | Methods for treating psychosis associated with interferson-α therapy |
| KR20050088079A (ko) | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이 |
| EP2319853B1 (en) * | 2002-12-12 | 2014-03-12 | IDENIX Pharmaceuticals, Inc. | Process for the production of 2'-branched nucleosides |
| RU2005123395A (ru) * | 2002-12-23 | 2006-01-27 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 3-нуклеозидных пролекарств |
| US7429572B2 (en) | 2003-05-30 | 2008-09-30 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| ES2303132T3 (es) | 2003-08-07 | 2008-08-01 | Zymogenetics, Inc. | Preparaciones homogeneas de il-29. |
| JP2007501806A (ja) * | 2003-08-13 | 2007-02-01 | ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー | ウィルス感染を治療する方法 |
| CA2537849A1 (en) * | 2003-09-11 | 2005-03-17 | F. Hoffmann-La Roche Ag | Process for preparing antiviral nucleoside derivatives |
| CA2558829C (en) * | 2004-04-02 | 2014-03-11 | Zymogenetics, Inc. | Methods for treating viral infection using il-28 and il-29 cysteine mutants |
| BRPI0512360A (pt) * | 2004-06-23 | 2008-03-11 | Idenix Cayman Ltd | derivados de 5-aza-7-deazapurina para o tratamento de flaviviridae |
| WO2006031725A2 (en) | 2004-09-14 | 2006-03-23 | Pharmasset, Inc. | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| CN101048172A (zh) * | 2004-10-29 | 2007-10-03 | 英特塞尔股份公司 | 用于慢性hcv患者的hcv疫苗 |
| US7705138B2 (en) * | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| NZ568324A (en) | 2005-11-11 | 2012-01-12 | Vertex Pharma | Hepatitis C virus variants |
| US7781576B2 (en) * | 2005-12-23 | 2010-08-24 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| EP2376088B1 (en) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | 6-O-Substituted-2-amino-purine nucleoside phosphoramidates |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
| EP2585065A1 (en) | 2010-06-24 | 2013-05-01 | Panmed Ltd. | Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent |
| WO2012045704A1 (en) | 2010-10-05 | 2012-04-12 | Novartis Ag | New treatments of hepatitis c virus infection |
| JP6110791B2 (ja) * | 2010-11-30 | 2017-04-05 | ノバルティス アーゲー | Ｃ型肝炎ウイルス感染症の新規治療 |
| AR084044A1 (es) | 2010-11-30 | 2013-04-17 | Pharmasset Inc | Compuestos 2’-espiro-nucleosidos |
| EP2691094A1 (en) | 2011-03-31 | 2014-02-05 | Novartis AG | Alisporivir to treat hepatitis c virus infection |
| AU2012241859A1 (en) | 2011-04-13 | 2013-10-10 | Debiopharm International Sa | Treatment of Hepatitis C virus infection with alisporivir |
| US8912141B2 (en) | 2011-06-23 | 2014-12-16 | Panmed Ltd. | Treatment of hepatitis C virus |
| JP6073897B2 (ja) | 2011-09-16 | 2017-02-01 | ギリアド ファーマセット エルエルシー | Ｈｃｖを処置するための方法 |
| WO2013045460A1 (en) | 2011-09-27 | 2013-04-04 | Novartis Ag | Alisporivr for treatment of hepatis c virus infection |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| ES2771458T3 (es) | 2013-01-31 | 2020-07-06 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
| WO2014122537A2 (en) | 2013-02-05 | 2014-08-14 | Genoscience Sa | Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin |
| PL3650014T3 (pl) | 2013-08-27 | 2022-01-31 | Gilead Pharmasset Llc | Preparat złożony dwóch związków przeciwwirusowych |
| CN111320662B (zh) * | 2020-02-17 | 2022-11-25 | 南京医科大学 | 一类n-苄基取代的二脒那秦衍生物及其药物用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3984396A (en) * | 1971-06-01 | 1976-10-05 | Icn Pharmaceuticals, Inc. | 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters |
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| GB1482736A (en) | 1974-03-18 | 1977-08-10 | Icn Pharmaceuticals | 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives |
| US4544741A (en) | 1982-03-29 | 1985-10-01 | Robins Roland K | Azole dinucleotide compounds and methods for their production |
| US5674911A (en) | 1987-02-20 | 1997-10-07 | Cytrx Corporation | Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use |
| US4925930A (en) | 1988-11-02 | 1990-05-15 | Nucleic Acid Research Institute | Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates |
| CA2129533A1 (en) * | 1992-02-10 | 1993-08-19 | Douglas Testa | Improved alpha interferon composition and method for its production from human peripheral blood leukocytes |
| GB9307043D0 (en) * | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| WO1997021452A2 (en) | 1995-12-14 | 1997-06-19 | Advanced Magnetics, Inc. | Macromolecular prodrugs of nucleotide analogs |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| WO1998021223A1 (en) | 1996-11-12 | 1998-05-22 | Medivir Ab | Nucleosides |
| RU2001113268A (ru) * | 1998-10-16 | 2003-09-27 | Шеринг Корпорейшн (US) | Сочетанная терапия рибавирином и интерфероном α для удаления определяемой рнк вируса гепатита с у пациентов с хроническим гепатитом с |
| US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| US6403564B1 (en) * | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| US6924270B2 (en) | 2000-04-20 | 2005-08-02 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| US6673775B2 (en) | 2001-04-18 | 2004-01-06 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
-
2001
- 2001-04-18 US US09/837,491 patent/US6924270B2/en not_active Expired - Fee Related
- 2001-04-18 WO PCT/US2001/012760 patent/WO2001081359A1/en active Application Filing
- 2001-04-18 AU AU2001255495A patent/AU2001255495A1/en not_active Abandoned
- 2001-04-18 EP EP01928662A patent/EP1282632A1/en not_active Withdrawn
- 2001-04-19 AR ARP010101840A patent/AR031572A1/es unknown
-
2004
- 2004-07-06 US US10/885,374 patent/US7115578B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001255495A1 (en) | 2001-11-07 |
| US7115578B2 (en) | 2006-10-03 |
| US6924270B2 (en) | 2005-08-02 |
| EP1282632A1 (en) | 2003-02-12 |
| WO2001081359A1 (en) | 2001-11-01 |
| US20020055473A1 (en) | 2002-05-09 |
| US20050004053A1 (en) | 2005-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031572A1 (es) | Derivados de ribavirina, composiciones farmaceuticas y el uso de los mismos solo o en combinacion para la preparacion de medicamentos para erradicar hcv-arn en pacientes que tienen infeccion cronica de hepatitis c | |
| ES2566973T3 (es) | Uso de SNS-595 para tratar leucemia | |
| BR112015018751A2 (pt) | derivados de piridazinona macrocíclicos | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| NO20052546L (no) | Substituert arylthiourea og relaterte forbindelser; inhibitorer av viral reproduksjon. | |
| DE60239939D1 (de) | Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung | |
| AR044526A1 (es) | Compuestos triciclicos moduladores de receptor nuclear de hormonas esteroides, composiciones farmaceuticas que los comprenden y su uso para la fabricacion de un medicamento. | |
| ECSP066313A (es) | Derivados de la piridazina y su uso como agentes terapéuticos | |
| AR056575A1 (es) | Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo | |
| MY128463A (en) | 4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus | |
| BR9915967A (pt) | Derivados de propanolamina substituìdos por arila, proceso para sua preparação, medicamentos contendo estes compostos e seu uso | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| CU20090209A7 (es) | Compuestos macrocíclicos como inhibidores de la replicación viral | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| NO20050573L (no) | 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler | |
| BRPI0408920A (pt) | difenilazetidinona com propriedades fisiológicas aperfeiçoadas, processo para a sua preparação, medicamentos contendo esses compostos e sua aplicação | |
| CL2011001413A1 (es) | Compuestos derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano; composicion farmaceutica que comprende a uno de los compuestos; y su uso en la preparacion de medicamentos para la prevencion o el tratamiento de una infeccion bacteriana. | |
| BR0016712A (pt) | Derivados do ácido n-benzil-indol-3-il-glioxìlico com efeito antitumor | |
| AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
| CA2430967A1 (en) | Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents | |
| NZ510811A (en) | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection | |
| AR034223A1 (es) | Novedosa indicacion terapeutica de azitromicina para el tratamiento de enfermedades inflamatorias no infecciosas | |
| BR9911300A (pt) | Composto, composição farmacêutica, e, uso do composto | |
| BRPI0012475A (pt) | composto derivado de titânio, seu processo de preparação e utilização, bem como composição para uso oral compreendendo o mesmo. | |
| SE0002476D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |